• français
    • English
  • français 
    • français
    • English
  • Ouvrir une session
Voir le document 
  •   Accueil de Bibliosante.ml
  • Université des Sciences, des Techniques et des Technologies de Bamako
  • Faculté de Pharmacie
  • Mémoires de spécialisations
  • Voir le document
  •   Accueil de Bibliosante.ml
  • Université des Sciences, des Techniques et des Technologies de Bamako
  • Faculté de Pharmacie
  • Mémoires de spécialisations
  • Voir le document
JavaScript is disabled for your browser. Some features of this site may not work without it.

Sérotypes de Streptococcus pneumoniae responsables de méningites bactériennes au Mali de 2014-2018

Thumbnail
Voir/Ouvrir
Hawa SANOGO.pdf (963.6Ko)
Date
2020
Auteur
Sanogo, Hawa
Metadata
Afficher la notice complète
Résumé
Introduction : In Mali Streptococcus pneumoniae has become the most implicated germ in bacterial meningitis after MenAfrivac and pentavalent vaccines introduction against meningococcus and Haemophilus influenzae type b. Although a vaccine introduced against Streptococcus pneumoniae in the Widen immunization Program, its frequency didn’t decrease. The objective of this study was to map the serotypes of Streptococcus pneumoniae circulating in Mali. Populations and methods : It was a descriptive cross-sectional study with retrospective collection. It was carried out as part of epidemiological surveillance of meningitis in Mali from january 2014 to December 2018 at the National Institute of Public Health. It concerned all LCS positive for Lyt A by real time technics witch quantity was allow for serotypage. All samples undergone quality control to confirm cases. Résultats : Study concerned 285 samples and Streptococcus pneumoniae was the most implicated germ with 52,80%. 37,0 % of samples (105/284 cases) was not typables by the real time PCR.On identified serotypes, the main one was serotype 1 with 24,58 % (44/179 cases) mostly into people who was 15-29 years old.the serotype 2 and 12F/12A/12B/44/46 represented for every one 18,99 % (34 cases) mainly identified in children who ages was under 1 year resectively 91,17% (31/34 cases) et 52,94% (18/34 cases). 46,4% was Prevnar 13® serotypes (83/179 cases) and 44, 1% the none -Prevnar 13® one (79/179 cases). Conclusion : The existence of included /or no serotypes in Prevnar 13® vaccine involved to review the vaccination strategies against invasive pneumococcal infections, which is the necessity to consider the elaboration of a new vaccine including those serotypes.
URI
Hawa;
Collections
  • Mémoires de spécialisations

DSpace software copyright © 2002-2016  DuraSpace
Contactez-nous | Faire parvenir un commentaire
Theme by 
Atmire NV
 

 

Parcourir

Tout Bibliosante.mlCommunautés & CollectionsPar date de publicationAuteursTitresSujetsCette collectionPar date de publicationAuteursTitresSujets

Mon compte

Ouvrir une sessionS'inscrire

DSpace software copyright © 2002-2016  DuraSpace
Contactez-nous | Faire parvenir un commentaire
Theme by 
Atmire NV